Skip to main content

16 Result(s)

within C. Massard Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors

    Notch signaling plays an integral role in development and tissue homeostasis. Inhibition of Notch signaling has been identified as a reasonable target for oncotherapy. Crenigacestat (LY3039478) is a potent Not...

    C. Massard, P. A. Cassier, A. Azaro, B. Anderson… in Cancer Chemotherapy and Pharmacology (2022)

  2. No Access

    Article

    Les actualités marquantes du congrès Targeted Anticancer Therapies — TAT 2016

    Le congrès TAT (targeted anticancer therapies) est dédié aux essais précoces et aux molécules innovantes en cours de développement. La session 2016 a permis d’apercevoir le futur de l’immunothérapie antitumorale ...

    R. Flippot, I. Bouallagui, P. du Rusquec, P. Gougis, C. Henon, A. Houessinon… in Oncologie (2016)

  3. No Access

    Article

    Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party

    Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced...

    A Necchi, R Miceli, M Bregni, C Bokemeyer, L A Berger… in Bone Marrow Transplantation (2016)

  4. No Access

    Article

    Les tumeurs germinales de stade métastatique

    Les tumeurs du testicule sont les cancers les plus fréquents de l’homme jeune. Depuis les années 1970, les tumeurs germinales métastatiques sont devenues le paradigme des cancers curables par l’utilisation de ...

    C. Massard, Y. Loriot, K. Fizazi in Oncologie (2014)

  5. No Access

    Article

    A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

    Background The kinesin spindle protein Eg5 is involved in mitosis, and its inhibition promotes mitotic arrest. EMD 534085, a potent, reversible Eg5 inhibitor, demonstrated significant pre...

    A. Hollebecque, E. Deutsch, C. Massard, C. Gomez-Roca… in Investigational New Drugs (2013)

  6. No Access

    Article

    Cibler le métabolisme tumoral : efficacité et perspectives

    Metabolic reprogramming is a hallmark of cancer which will provide tumor cells with all metabolites needed for growth and proliferation. Numerous oncogenes are responsible for a cellular metabolic reprogrammin...

    J. Hadoux, C. Massard in Oncologie (2013)

  7. Article

    Erratum: hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway

    Correction to: Oncogene (2006) 25, 4505–4514; doi:10.1038/sj.onc.1209487; published online 17 April 2006 Errors were inadvertently included in Figure 3a of the article mentioned above. In particular, represent...

    C Massard, Y Zermati, A-L Pauleau, N Larochette, D Métivier, L Sabatier… in Oncogene (2013)

    Download PDF (328 KB) View Article

  8. No Access

    Article

    Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

    Background ES-285 (spisulosine) is a novel compound derived from the marine mollusk Spisula polynoma with evidence of preclinical antitumor activity. This phase I clinical trial was designed to i...

    C. Massard, R. Salazar, J. P. Armand, M. Majem, E. Deutsch… in Investigational New Drugs (2012)

  9. No Access

    Article

    Agents antiangiogéniques et association de TMC: attention danger

    Greater knowledge in cancer biology has led to the isolation of molecular targets implicated in cell physiology. New treatments blocking a specific molecular target, in particular compounds blocking kinase act...

    C. Massard in Oncologie (2012)

  10. No Access

    Article

    Les thérapies ciblées de l’os métastatique: soins de support ou traitements de fond ?

    Bone metastases in prostate cancer treatment stand as a clinical challenge in order to maintain quality of life and prevent pain and skeletal-related events. Bone metastases predominantly disrupts the dynamic ...

    L. Albiges, C. Massard, Y. Loriot, K. Fizazi in Oncologie (2012)

  11. No Access

    Article

    Rhinitis and epistaxis in patients treated by anti-angiogenic therapy

    Anti-angiogenic therapies have a particular drug-related toxicity profile including hypertension, thrombosis, haemorrhages, and proteinuria. Moreover, patients treated by angiogenesis inhibitors present nasal ...

    V. Prulière-Escabasse, E. Escudier, R. Balheda, J. C. Soria… in Investigational New Drugs (2009)

  12. No Access

    Article

    Chimiothérapie des CAPI: quelles leçons peut-on en tirer en 2008 ?

    Chemotherapy is the backbone of treatment forpatients with CUP. Most patients with unknown primary adenocarcinoma or poorly differentiated carcinoma do not conform to any previously defined “treatable” or favo...

    C. Massard, K. Fizazi in Oncologie (2008)

  13. No Access

    Article

    Autogreffe dans les cancers du testicule

    Les patients atteints de tumeurs germinales sont en grande majorité guéris par le traitement de chimiothérapie à base de platine et la chirurgie des masses résiduelles. Cependant, le groupe de patients de mauv...

    C. Massard, K. Fizazi in Oncologie (2007)

  14. No Access

    Article

    Inhibiteurs de tyrosine kinase ciblant le VEGFR

    L'angiogénèse est un mécanisme central dans le processus de croissance tumorale et de métastases. La famille du VEGF et des récepteurs au VEGF est un des régulateurs les plus importants de l'angiogenèse. Diffé...

    Y. Loriot, C. Massard, J.-P. Armand in Oncologie (2006)

  15. No Access

    Article

    hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway

    hTERT is the catalytic subunit of the telomerase and is hence required for telomerase maintenance activity and cancer cell immortalization. Here, we show that acute hTERT depletion has no adverse effects on th...

    C Massard, Y Zermati, A-L Pauleau, N Larochette, D Métivier, L Sabatier… in Oncogene (2006)

  16. No Access

    Article

    Actualités de l’ASCO 2006

    Les thérapies moléculaires ciblées ont modifié les stratégies de traitements de plusieurs cancers et ouvrent de nouvelles perspectives dans la prise en charge des patients. Cette année, deux études de phase II...

    C. Massard in Oncologie (2006)